Inside Retatrutide's TRIUMPH Basket-Trial Design

What Is a Basket Trial, and Why Does Retatrutide's Programme Use One?

Most of the retatrutide headlines researchers see — weight loss, A1C, joint pain, sleep-apnoea severity — come from a single umbrella programme called TRIUMPH. A January 2026 paper in Diabetes, Obesity and Metabolism lays out the rationale and design behind it in more methodological detail than any topline press release provides, and it is worth reading on its own terms rather than only for the efficacy numbers it precedes.[1]

The central design choice is a basket trial: a master protocol that tests one drug across multiple, often co-occurring, disease subgroups within a single study population, instead of recruiting a fully separate cohort and running a fully separate trial for each condition. Obesity, obstructive sleep apnoea (OSA) and knee osteoarthritis (OA) frequently occur together in the same patients, so a basket design lets retatrutide (LY3437943) generate registrational-quality data on all three from one recruitment effort, rather than three.[1]

How Is TRIUMPH-1 Structured as a Basket Trial?

The OSA and OA cohorts are not separate trials bolted onto TRIUMPH-1 after the fact; they are pre-specified sub-studies of participants who happened to qualify for the main obesity trial and had a co-existing diagnosis of OSA or knee OA at baseline. Each basket carries its own pre-specified primary endpoint (AHI reduction for OSA, WOMAC pain reduction for OA) analysed within the wider TRIUMPH-1 dataset, which is why a single 80-week trial can support three distinct sets of headline results.[2] For the full TRIUMPH-1 obesity and basket-trial results, see our dedicated TRIUMPH-1 guide.

Why Did TRIUMPH-4 Follow as a Standalone Confirmatory Trial?

A nested basket sub-study is efficient, but regulators generally still want a dedicated, adequately powered trial confirming an indication before it can support a specific label claim. That is the role TRIUMPH-4 plays for knee osteoarthritis: rather than relying solely on TRIUMPH-1's 574-participant OA basket, Lilly ran a standalone, purpose-built Phase 3 trial of 445 participants over 68 weeks, randomised 1:1:1 to retatrutide 9 mg, 12 mg or placebo (NCT05869903).[1] On the 12 mg dose, participants lost an average of 28.7% body weight and reported a 75.8% reduction in WOMAC pain, consistent with the basket-trial signal seen a year earlier in TRIUMPH-1.

This two-step pattern — a basket sub-study inside the master obesity trial, followed by a standalone confirmatory trial for the indication that basket flagged as promising — is a useful thing for researchers to recognise across incretin-class development generally, not just for retatrutide. It lets a sponsor screen several comorbidities cheaply within one programme, then commit dedicated trial resources only to the ones the basket data actually supports. For the full osteoarthritis dataset, see our retatrutide and knee osteoarthritis guide.

Where Do TRIUMPH-2, TRIUMPH-3 and TRIUMPH-5+ Fit In?

TRIUMPH-1 and TRIUMPH-4 are only two parts of a five-trial-plus programme. The other studies are conventional single-indication Phase 3 trials rather than baskets, each targeting a specific complication of obesity:

TRIUMPH-2's full Phase 3 dataset is scheduled for presentation at a dedicated EASD symposium on 30 September 2026 — see our EASD 2026 coverage for what is and is not new there. TRIUMPH-3, evaluating hard cardiovascular endpoints (MACE) in people with established cardiovascular disease, remains ongoing, with results expected later in 2026. Lilly has indicated that seven further Phase 3 readouts across the wider programme are expected through 2026, spanning MASLD, chronic low back pain and additional cardiovascular follow-up.

Why Does This Design Matter for Reading Retatrutide Research?

For researchers tracking this literature, the practical value of understanding basket-trial design is knowing which headline numbers come from the same underlying dataset and which come from an independent replication. The 60.6% AHI reduction and 73.1% WOMAC pain reduction reported from TRIUMPH-1 are basket sub-study findings within a trial primarily powered for the weight-loss endpoint; they are not the same statistical standard as TRIUMPH-4's standalone, purpose-powered 75.8% WOMAC result. Both are real, reported findings, but conflating a basket sub-study with a dedicated confirmatory trial overstates how independently a result has been verified — a distinction that matters when comparing retatrutide's evidence base to a single-indication programme.

What Should UK Researchers Take From This?

Nothing here changes retatrutide's UK regulatory status: it remains an unlicensed, investigational compound with no MHRA marketing authorisation for obesity, OSA, knee osteoarthritis or any other indication, and nothing in this article constitutes a therapeutic or health claim. Velox Peptides supplies retatrutide strictly as an HPLC-verified in vitro research reagent, with no health or therapeutic claims made for it.

This compound is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions